284 related articles for article (PubMed ID: 9720967)
1. Modulatory effects of L-DOPA on D2 dopamine receptors in rat striatum, measured using in vivo microdialysis and PET.
Opacka-Juffry J; Ashworth S; Ahier RG; Hume SP
J Neural Transm (Vienna); 1998; 105(4-5):349-64. PubMed ID: 9720967
[TBL] [Abstract][Full Text] [Related]
2. L-DOPA inhibits depolarization-induced [3H]GABA release in the dopamine-denervated globus pallidus of the rat: the effect is dopamine independent and mediated by D2-like receptors.
Silva I; Cortes H; Escartín E; Rangel C; Florán L; Erlij D; Aceves J; Florán B
J Neural Transm (Vienna); 2006 Dec; 113(12):1847-53. PubMed ID: 16736236
[TBL] [Abstract][Full Text] [Related]
3. Effect of L-dopa and 6-hydroxydopamine lesioning on [11C]raclopride binding in rat striatum, quantified using PET.
Hume SP; Opacka-Juffry J; Myers R; Ahier RG; Ashworth S; Brooks DJ; Lammertsma AA
Synapse; 1995 Sep; 21(1):45-53. PubMed ID: 8525461
[TBL] [Abstract][Full Text] [Related]
4. The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats.
Treseder SA; Rose S; Jenner P
Eur J Neurosci; 2001 Jan; 13(1):162-70. PubMed ID: 11135014
[TBL] [Abstract][Full Text] [Related]
5. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors.
Antonini A; Schwarz J; Oertel WH; Beer HF; Madeja UD; Leenders KL
Neurology; 1994 Jul; 44(7):1325-9. PubMed ID: 8035939
[TBL] [Abstract][Full Text] [Related]
6. In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels.
Mela F; Marti M; Bido S; Cenci MA; Morari M
Neurobiol Dis; 2012 Jan; 45(1):573-82. PubMed ID: 22001605
[TBL] [Abstract][Full Text] [Related]
7. Striatal D2 dopamine receptor status in Parkinson's disease: an [18F]dopa and [11C]raclopride PET study.
Dentresangle C; Veyre L; Le Bars D; Pierre C; Lavenne F; Pollak P; Guerin J; Froment JC; Brousolle E
Mov Disord; 1999 Nov; 14(6):1025-30. PubMed ID: 10584682
[No Abstract] [Full Text] [Related]
8. Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naïve parkinsonism. Diagnostic implications of the D2 receptor status.
Sawle GV; Playford ED; Brooks DJ; Quinn N; Frackowiak RS
Brain; 1993 Aug; 116 ( Pt 4)():853-67. PubMed ID: 8353712
[TBL] [Abstract][Full Text] [Related]
9. Quantitation of carbon-11-labeled raclopride in rat striatum using positron emission tomography.
Hume SP; Myers R; Bloomfield PM; Opacka-Juffry J; Cremer JE; Ahier RG; Luthra SK; Brooks DJ; Lammertsma AA
Synapse; 1992 Sep; 12(1):47-54. PubMed ID: 1411963
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum.
Lopez A; Muñoz A; Guerra MJ; Labandeira-Garcia JL
Neuroscience; 2001; 103(3):639-51. PubMed ID: 11274784
[TBL] [Abstract][Full Text] [Related]
11. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
Antonini A; Schwarz J; Oertel WH; Pogarell O; Leenders KL
Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
[TBL] [Abstract][Full Text] [Related]
12. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Hossain MA; Weiner N
J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
[TBL] [Abstract][Full Text] [Related]
13. In vivo antagonism of the behavioral responses to L-3-,4-dihydroxyphenylalanine by L-3-,4-dihydroxyphenylalanine cyclohexyl ester in conscious rats.
Matsushita N; Misu Y; Goshima Y
Eur J Pharmacol; 2009 Mar; 605(1-3):109-13. PubMed ID: 19168057
[TBL] [Abstract][Full Text] [Related]
14. Experimental studies and theoretical aspects on A2A/D2 receptor interactions in a model of Parkinson's disease. Relevance for L-dopa induced dyskinesias.
Antonelli T; Fuxe K; Agnati L; Mazzoni E; Tanganelli S; Tomasini MC; Ferraro L
J Neurol Sci; 2006 Oct; 248(1-2):16-22. PubMed ID: 16765381
[TBL] [Abstract][Full Text] [Related]
15. Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease.
Rinne UK; Laihinen A; Rinne JO; Någren K; Bergman J; Ruotsalainen U
Mov Disord; 1990; 5(1):55-9. PubMed ID: 2136932
[TBL] [Abstract][Full Text] [Related]
16. Endogenously released L-dopa itself tonically functions to potentiate postsynaptic D2 receptor-mediated locomotor activities of conscious rats.
Yue JL; Nakamura S; Ueda H; Misu Y
Neurosci Lett; 1994 Mar; 170(1):107-10. PubMed ID: 7913742
[TBL] [Abstract][Full Text] [Related]
17. Ketamine decreased striatal [(11)C]raclopride binding with no alterations in static dopamine concentrations in the striatal extracellular fluid in the monkey brain: multiparametric PET studies combined with microdialysis analysis.
Tsukada H; Harada N; Nishiyama S; Ohba H; Sato K; Fukumoto D; Kakiuchi T
Synapse; 2000 Aug; 37(2):95-103. PubMed ID: 10881030
[TBL] [Abstract][Full Text] [Related]
18. Impact of L-dopa on striatal acetylcholine release: effects of 6-hydroxydopamine.
Jackson D; Abercrombie ED; Zigmond MJ
J Pharmacol Exp Ther; 1993 Nov; 267(2):912-8. PubMed ID: 8246167
[TBL] [Abstract][Full Text] [Related]
19. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
Tedroff J; Pedersen M; Aquilonius SM; Hartvig P; Jacobsson G; Långström B
Neurology; 1996 May; 46(5):1430-6. PubMed ID: 8628494
[TBL] [Abstract][Full Text] [Related]
20. Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies.
Turjanski N; Lees AJ; Brooks DJ
Neurology; 1999 Mar; 52(5):932-7. PubMed ID: 10102408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
